Thanks to an infusion of funding from a consortium of investors, CRO Inclinix has merged with integrated site network PMG Research. With the two combining forces, the companies will establish an organization meant to accelerate clinical trial enrollment from beginning to end, according to a statement.
"This novel business combination will allow sponsors and CROs to bundle the two most important services in a trial: world class sites and patient recruiting," as stated by J. Tobin Geatz, who will take the reins as president and CEO of the newly-christened Inclinix-PMG Holdings. By combining the talents of more than 200 PMG principal investigators and study coordinators, with that of Inclinix's 75-plus enrollment managers, the merged company hopes to accelerate clinical trial enrollment.
The merger comes at a time when patient enrollment seems to lag. Experts are puzzled as to why enrollment in clinical cancer trials is so low, but think it could do with insurance and age concerns with older patients. Pediatric clinical trials also have similar problems when it comes to parental consent and market profitability of pediatric drugs.
The cost of the merger was not disclosed.
- here's the release
- see more from PharmaTimes